EUVIMEDEUVIMED entdecken
Crossref

Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma

Bingyi Lin iD, Siyuan Chai, Qijun Zhang, Yuejie Lu, Jiahao Hu, Jie Zhang, Yong-Zhong Du iD, Liming Wu iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.3c00451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Bingyi Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 310003, Zhejiang…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Primary Research and Development Plan of Zhejiang Province, National Key Research and Development Program of China, Department of Health of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

O-linked-N-acetylglucosaminylation (O-GlcNAcylation) plays a key role in hepatocellular carcinoma (HCC) development, and the inhibition of O-GlcNAcylation has therapeutic potential. To decrease the systemic adverse events and increase targeting, we used sialic acid (SA)-decorated liposomes loaded with OSMI-1, an inhibitor of the O-GlcNAcylation, to further improve the anti-HCC effect. Fifty pairs of HCC tissue samples and the cancer genome atlas database were used to analyze the expression of O-GlcNAc transferase (OGT) and its effects on prognosis and immune cell infiltration. OSMI-1 cells were treated with SA and liposomes. Western blotting, immunofluorescence, cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, immunohistochemistry, and tumorigenicity assays were used to investigate the antitumor effect of SA-modified OSMI-1 liposomes in vitro and in vivo. OGT was highly expressed in HCC tissues, negatively correlated with the degree of tumor infiltration of CD8+ and CD4+T cells and prognosis, and positively correlated with the degree of Treg cell infiltration. SA-modified OSMI-1 liposome (OSMI-1-SAL) was synthesized with stable hydrodynamic size distribution. Both in vitro and in vivo, OSMI-1-SAL exhibited satisfactory biosafety and rapid uptake by HCC cells. Compared to free OSMI-1, OSMI-1-SAL had a stronger capacity for suppressing the proliferation and promoting the apoptosis of HCC cells. Moreover, OSMI-1-SAL effectively inhibited tumor initiation and development in mice. OSMI-1-SAL also promoted the release of damage-associated molecular patterns, including anticalreticulin, high-mobility-group protein B1, and adenosine triphosphate, from HCC cells and further promoted the activation and proliferation of the CD8+ and CD4+T cells. In conclusion, the OSMI-1-SAL synthesized in this study can target HCC cells, inhibit tumor proliferation, induce tumor immunogenic cell death, enhance tumor immunogenicity, and promote antitumor immune responses, which has the potential for clinical application in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMiceAnimalsLiposomesN-Acetylneuraminic AcidCell ProliferationN-Acetylglucosaminyltransferases

Stichwörter der Autor:innen

O-GlcNAc transferase inhibitorOSMI-1hepatocellular carcinomalipidosometumor microenvironment

Substanzen

LiposomesN-Acetylneuraminic AcidO-GlcNAc transferaseN-Acetylglucosaminyltransferases

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 310003, Zhejiang Province, China.
  • Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310030, Zhejiang Province, China.
  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Jiaxing University, School of Medicine, Jiaxing 314001, Zhejiang Province, China.

ORCID-Profile: Bingyi Lin, Yong-Zhong Du, Liming Wu

Förderung

  • Primary Research and Development Plan of Zhejiang Province
  • National Key Research and Development Program of China
  • Department of Health of Zhejiang Province
  • Natural Science Foundation of Zhejiang Province
  • Science and Technology Bureau of Jiaxing City

Zitieren

APA

Lin, B., Chai, S., Zhang, Q., Lu, Y., Hu, J., Zhang, J., Du, Y. Z., & Wu, L. (2024). Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00451

Vancouver

Lin B, Chai S, Zhang Q, Lu Y, Hu J, Zhang J, et al. Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00451

BibTeX
@article{Lin2024,
  author = {Lin, Bingyi and Chai, Siyuan and Zhang, Qijun and Lu, Yuejie and Hu, Jiahao and Zhang, Jie and Du, Yong-Zhong and Wu, Liming},
  title = {Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.3c00451}
}
Kostenlos starten →